[go: up one dir, main page]

WO2025049491A1 - Nouvel échantillonnage et comparaison génétique et analyse de composants du cannabis pour une différenciation commerciale - Google Patents

Nouvel échantillonnage et comparaison génétique et analyse de composants du cannabis pour une différenciation commerciale Download PDF

Info

Publication number
WO2025049491A1
WO2025049491A1 PCT/US2024/044062 US2024044062W WO2025049491A1 WO 2025049491 A1 WO2025049491 A1 WO 2025049491A1 US 2024044062 W US2024044062 W US 2024044062W WO 2025049491 A1 WO2025049491 A1 WO 2025049491A1
Authority
WO
WIPO (PCT)
Prior art keywords
genetic
receptors
cannabis
receptor
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/044062
Other languages
English (en)
Inventor
Jon Wood
Anthony LOZAMA JR.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genopheno LLC
Original Assignee
Genopheno LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genopheno LLC filed Critical Genopheno LLC
Publication of WO2025049491A1 publication Critical patent/WO2025049491A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
    • H04L9/50—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols using hash chains, e.g. blockchains or hash trees
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/13—Plant traits
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present embodiments generally relate to validation of cannabis compositions. Embodiment relate to both the specific acquisition of cannabis materials herein unto difficult to obtain and transport as well as the processing for proper analysis and verification of: chemical composition, genetic makeup and presence of key plant component characteristics, and origin including lineage certification.
  • the methods described herein provide quantitation and qualification of chemical compounds of interest via methods of self-contained extraction and sample preparation.
  • the methods are facilitated via utilization of a Novel cassette cartridge apparatus.
  • the methods also use genetic measurements taken from sample or legacy plant and alleged offspring or clone to determine whether the alleged clone is legitimate as compared to parent.
  • the methods also allow for genetic testing and determination of key enzymes and expression of said enzyme involved in the production of chemical compounds of interest. BACKGROUND OF THE INVENTION [003]
  • the recreational use of cannabis has been noted for decades. Since the early 1900s, laws and mandates have restricted its usage, possession, and distribution.
  • Cannabis strains comprising CBD and other cannabinoids are highly differentiated; consequently, when genetically isolated, strains and resulting byproducts from strains proven to trigger specific biologically relevant receptors.
  • Clonership is a process of proving parentage or genetic replication within a scientific (range) of accuracy. This is accomplished by way of an informatics-based method that can compare two or more genetic profiles. Once proven, the product may be certified to carry the brand, thereby honestly signaling the brand’s medicinal value to the market.
  • Each of these critical elements will be made possible via the utilization of the innovation of sample collection/processing/analysis described herein.
  • Figure 1 depicts ligand/target interactions.
  • Figure 2 depicts the bottom half of a cassette.
  • Figure 3 depicts the internal shell of the cassette.
  • Figure 4 depicts the inner workings and mechanical grinding action of the cassette.
  • Figure 5 depicts the front of the cassette.
  • Figure 6 provides an assortment of key intermediates as well as the meroterpenoids of interest within a cannabis plant.
  • Figure 7 depicts a schematic representation of a genetic comparison and analysis system.
  • Figure 8 depicts a schematic representation of a genetic identification and supply chain verification/validation process.
  • Figure 9 depicts a schematic representation of a central laboratory system.
  • Figure 10 depicts a schematic representation of a satellite laboratory.
  • Figure 11 depicts a schematic representation of a public blockchain system.
  • Figure 12 depicts a schematic representation of a private blockchain system.
  • Figure 13 depicts a schematic representation of Dynamic Non-Fungible Token (dNFT) usage for Identification and Branding
  • Figure 14 provides exemplary cannabinoid and dopaminergic receptors.
  • dNFT Dynamic Non-Fungible Token
  • Figure 15 depicts formulation table for dynamic scoring of affinity, efficacy, selectivity, and enzyme analysis
  • Figure 16 depicts an example of the formulation table for dynamic scoring of affinity, efficacy, selectivity, and enzyme analysis 88209.413709
  • Figure 17 depicts an example of a receptor’s affinity and efficacy scoring with in the assay engine & resolver module in the CDR System
  • Figure 18 depicts an example of a receptor’s enzyme fidelity scoring within the enzyme detection and analysis module in the CDR System
  • Figure 19 depicts a dynamic scoring module – scoring example within the CDR system.
  • Figure 20 depicts a dynamic scoring module – match criteria central data repository (CDR) system.
  • CDR central data repository
  • Figure 21 depicts Clonorship Module match criteria with CDR system.
  • Figure 22 depicts dNFT and fractional dNFT Workflow.
  • Figure 23 depicts CDR blockchain/ERP Workflow. DETAILED DESCRIPTION
  • the terms “including” and “comprising” are open-ended terms and should be interpreted to mean “including, but not limited to. . . . " These terms encompass the more restrictive terms “consisting essentially of” and “consisting of.” [040] It must be noted that as used herein and in the appended claims, the singular forms "a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise.
  • the embodiments described herein are comprised of three essential parts: the genetic identification of cannabis, non-fungible traceability of identified cannabis throughout the supply chain process, and non-fungible certification of cannabis providing consumers’ verification of its genetic value and authenticity.
  • the genetic authentication of cannabis is dependent on several bases. The embodiments depend on testing parameters of cannabis materials, including specific genetic analysis via comparison of genetic measurements.
  • the methods 88209.413709 comprise pathways to the material collection as well as material processing.
  • meroterpenoids are the specific secondary metabolites produced by cannabis plants.
  • meroterpenoids include but are not limited to cannabidiol, cannabidiolic acid, cannabinol, cannabidiolic acid, cannabigerol, cannabinolic acid, cannabielsoin, cannabigerolic acid, cannabidivarin, cannabichromeric acid, trans- ⁇ -8-tetrahydrocannabinol, and/or trans- ⁇ -9- tetrahydrocannabinol.
  • Each of these different compounds is present in varying concentrations depending on the strain of the plant.
  • concentrations of these compounds are in part predicated on the presence and overall expression of particular cellular processes that dictate the formation and synthesis of said compounds including the presence of specific enzymes.
  • the enzymes and expression are contingent on single nucleotide polymorphisms (SNPs). These ratios can be used to identify specific strains of cannabis and help ensure the amount and quality of compounds of interest.
  • SNPs single nucleotide polymorphisms
  • Non-fungible traceability enables genetic authentication in the supply chain. This creates the potential for increased price elasticity, as the genetic identity and its value potential can be proven. The genetic identity and authentication is documented using blockchain infrastructure, ensuring it cannot be copied, 88209.413709 substituted, or mistaken for another genetic signature.
  • Non-fungible certification enables genetic authentication for consumers. Consumers use unique identifiers, i.e., dynamic nun-fungible tokens (dNFT) to access the genetic identity of a product or its comparative ranking against products with similar attributes. They can use computer applications to scan this unique identifier and find all off-chain data attributed to the product.
  • dNFT dynamic nun-fungible tokens
  • Cannabis source materials can be collected with the sampler kit and will be tested via the process therein.
  • the cassette facilitates the screening and analysis of acquired materials via internally contained sample prep that lends to further examination. Extraction and isolation of particular components through the sample prep are streamlined, allowing for rapid access and testing up to and including the previously mentioned. Novel genetic testing parameters and species identification from a procured sample. This is achieved without the need to undergo extensive pre- processing and transport to the testing facility within an enclosed loop, thus 88209.413709 potentially transporting to processing labs with respect to by-laws and guidelines of various municipalities. [047]
  • the sample collection and preparation described herein can be used and it will be evident to those skilled in the art that the described methodology can be utilized without explicit details within each step.
  • Plant material such as a stem
  • the cassette is a self-contained unit composed of high-density polyethylene (HDPE).
  • the internal shell is separately encapsulated inside the larger housing unit to ensure security and fidelity of the sample through transport and processing.
  • the outer shell is also composed of HDPE with a centralized port that directly links to the cassette's inner core, where the sample can be passed through.
  • the double shell approach solves the shortcomings of several currently used storage models for plant materials.
  • the internal shell of the cassette ( Figure 4) holds within a mechanical grinder, which is able, with high precision, to macerate samples into a powder/pulp mixture, which since self-encapsulated through double shell design, is incapable of leakage or sample loss after processing.
  • the cassette solves a significant problem during sample prep as plant samples are often macerated in external blending or grinding devices, and the precision of transfer of pulverized material to further the process of distillate and isolate formation is within 88209.413709 doubt and question.
  • the innovative approach presented by the cassette eliminates this problem, as initial sample processing is self-contained with no transfer points occurring, resulting in the high unlikelihood that the sample will be lost and unable to be further carried on through additional sample prep, extraction, isolation processes, etc.
  • the mechanical grinder ( Figure 4) is located, e.g., centrally, within an inner core of the inner shell (3).
  • the HDPE construction of the inner shell includes that of a non-stick HDPE inner surface. This further facilitates and ensures the lack of loss from sample processing which is seen and documented in other sample preps, including transfer cases and cassettes of different construction from what is presented here.
  • the mechanical grinder can be operated via a manual control unit located on the side of the cassette. Hand operation is able to disrupt the fidelity of sample via the sheer forces of the gears, and more pressure applied and push force applied to the manual apparatus will result in higher sheer forces on the contained sample, allowing sample submitted or end use processor to prepare sample for further processing before or after transport or storage within a self-contained unit.
  • the grinding gears will contact with submitted materials in a top-down manner where the grinder (4) will be in direct contact with sample material in the main storage compartment (3) ( Figure 4).
  • the HDPE coating 88209.413709 again facilitates smooth processing as a sample, even with the friction created from grinding/maceration of the gears, will not stick, ensuring that all available sample is available for further processing.
  • particular reagents including organic solvents, can make available compounds of interest for extraction and analysis without destroying the fidelity of genetic materials that also may be examined within 1-pot of the device.
  • the meroterpenoids that are present in highest concentrations as per insinuated by literature are all organic solvent soluble with various levels of lipophilicity.
  • reagent port itself allows for the existence of this newly made fluid mash to be stored securely and sealed within the cassette, facilitating transport of a pre-processed sample to a testing facility.
  • One aspect is that the pre-processing can now be conducted before sending out samples to where experimentation of extraction methods can occur from core user before sending out for sampling, resulting in potential cost savings on processing for back-end users while avoiding the potential issue of unknown extraction processes that may occur when just a raw sample is sent.
  • This feature in the cassette introduces more control and opportunity for a front-end user to sample prepare their own sample to standards agreed upon by the internal user before being sent off to central testing lab.
  • Mixtures within the cassette on the back end with testers can then be removed from the cassette via precision syringe in order to assist in analysis (Figure 5).
  • the original raw material sample can be simply stored within the container and itself shipped off for processing at a designated testing facility 88209.413709 without the need for sample prep and examination of the target compounds of interest.
  • Samples collected can be separately utilized via the presently presented sealed container for particular % presence of compounds of interest.
  • 90% ethanol can be injected to the sample cassette for initial extraction of related compounds of interest pull.
  • a sulfuric or some other aqueous acidic reagent can be then added into the cassette via the injection port.
  • This acid wash facilitates the formation of distillate by facilitating the removal of excipients that are more water soluble than organic in nature as for example, cannabinoid/meroterpenoids prefer organic solvents.
  • ethyl acetate can be introduced to create an organic layer cut in which choice materials should gravitate towards. Uncharged, lipophilic molecules derived from plant materials of interest will then be located within this organic layer, with non-wanted material located in aqueous, thus allowing for transport and storage of processed sample to testing facility without worry of contamination via transport. This is significant as the removal of contamination during or on back end of transport before testing as now been significantly mitigated, which to according to current knowledge, is not addressed via other technologies.
  • samples can be removed to facilitate the further testing of compound percentage make up from sample.
  • di-ethyl ether can also be utilized as extracting solvent for meroterpenoids of interest. These solvent cuts of compound again will be self-contained within the inner shell and removed upon extraction from the cassette at the Central Laboratory for further analytical testing including comparison against noted in-house control samples of meroterpenoids of interest.
  • Standardized samples of each of the meroterpenoids of interest will be used to analyze and determine the presence of meroterpenoids within the sample.
  • the assay consists of specific and isolated cells for a series of central nervous system relevant receptors, linked to known biology and pharmacology of clinically relevant outcomes. These include but are not limited to the dopamine receptor system, serotonin receptor system and opioid receptor system.
  • receptors will be derived from standard practices of cloning into Chinese hamster ovary (CHO) cells, as found in previous literature, and expressed in vitro as CHO as an expression and testing system is well established in practice. Upon expression of particular receptors of interest, compound will be measured for affinity and then efficacy using standardized assays, as found in literature. 88209.413709 Compounds derived will be screened across selected CNS receptors of interest to determine attuned ratios of activity. [061]
  • the cassette technology has the capability to simplify not only transport of samples of interest, but also makes sample prep simplified for not only analytical chemistry and subsequent qualitative and quantitative measurement but also in conjunction with facile application to pharmacological assays to determine biological activity both from a potency and selective standpoint.
  • the ability to take processed samples straight from the cassette to apply to in vitro pharmacological assays is unique as it is, according to current knowledge, the first use in a manner like this for rapid utilization. This avoids the issue that currently exists with sample preparation for assays as; less than perfect samples gives potentially misleading results including lack of activity or hyperactivity or lack of selectivity of samples.
  • the meroterpenoids of interest are secondary metabolites produced from cannabis plants in varying quantities. These are in large part determined by the presence and activity of particular enzymes within the plant that dictate the production of these compounds. These enzymes themselves are coded by proteins, which in turn are determined by particular genes.
  • the cassette could serve as a sterile, safe and secure storage or holding unit to either long-term store or ship plant material.
  • the cassette can also act as a sample processing unit via its ability to process sample either on-site from the donor of material or at the Central Laboratory once the sample is sent out.
  • the disadvantages seen with other known sample preparations lie in the difficulty to pre-process a sample to send off for testing without loss of material or potential exposure to contamination and sample risk.
  • the present embodiments offer mitigation around this shortcoming seen with other sample preparations while also providing on the back end, a fully processed sample without loss of valuable material that can occur during transport due to the dual shell design.
  • a processed sample that can be contained with the cassette facilitates ease of further genetic testing.
  • the cassette serves as a tool for dual sample preparation for plant analysis.
  • Samples housed within the syringe will be further processed via exposure to neutralizing agents, followed by an alcohol wash to precipitate out target materials. These steps can/will occur in an adjoining sample preparation kit.
  • the sample prep kit itself includes reagents to facilitate analysis on a chemical/biological standpoint. These include various lysing agents for cell wall and membrane breakdown, neutralizing agents to stabilize sample and astringents to foster sample work-up as similarly seen in standard wet-labs.
  • the kit will contain select -ases (lysing tools), in 88209.413709 addition to organic alcohol solvent, charcoal based neutralizer and distilled water washes.
  • Target material in the alcohol precipitate can be dissolved in water via syringe and injected back into the storage port of the sealed container where it is suitable for storage and/or transport (7). Conversely, the original raw material sample can be simply stored within the container and itself shipped off for processing at designated testing facility without the need for sample preparation. [067] These embodiments allow for mitigation against two current disadvantages. 1. Non-processed samples often are exposed to possible contamination during packaging or transport, which may disrupt accuracy of testing on back end for laboratory facilities. 2. Transport of certain plant materials across jurisdictions is potentially problematic. The cassette presents an enclosed system to help avoid shipping issues as well as a stable system of transporting pre-processed samples that will retain quality for rigorous testing which also helps avoid against any jurisdiction restrictions around work with plant materials.
  • the Central Laboratory System contains all Receptor Assays, which act as the control group by which scientific samples are compared. These assays are designed to test scientific sample affinity, selectivity, and efficacy against specific physical receptors Assays as previously described will determine affinity, efficacy and selectivity to particular receptors of interest within the central nervous system, including dopaminergic, serotonergic and opioid receptors in a manner where compounds derived from samples of interest will be challenged against selected particular receptors for ability to bind as well as activate. . The measurement and scoring of each scientific sample establish a Novel numeric value. These values allow for a Dynamic Ranking of all other scientific samples in the Central Laboratory Database associated with a specific receptor.
  • Blockchain-based time-stamping process records data within the blockchain system, proving the Scientific 88209.413709 Sample’s existence and performance metrics relative to other scientific samples at a specific time and date (Figure 8).
  • the time-stamped, decentralized universe of genetic data and its comparative relativity to specified physical receptors is a Novel market feature.
  • the Central Laboratory System is connected to Satellite Laboratories ( Figure 9) by a network of decentralized blockchain nodes within a public blockchain system, comprising the GenoPheno System ( Figure 10).
  • Scientific Sample data enters into the Central Laboratory System using the public blockchain interface module; the blockchain node generates a time-stamp, enabling real-time rankings of Scientific Sample receptor performance.
  • the Central Laboratory System accepts the Scientific Sample and may compare Scientific Sample to Novel receptor assay datasets within the Central Laboratory’s Assay Engine and Resolver Module. Scientific Samples are scored, compared, then ranked against all other Scientific Samples in the system. [071] A sample’s rankings may change with each officially recorded and calculated ranking updated in the system. Each ranking is able to provide quantitative and qualitative insight into sample submitted as the ranking examines both genotype and phenotype qualities with subsequent available in vitro pharmacology. The first time a sample enters the system it is genetically authenticated, once authenticated it is referred to as a Scientific Sample and is compared to receptor assays, and its potency is determined. Potency being defined as affinity along with efficacy as well as selectivity.
  • Scientific samples may have multiple representations including: seeds, plants and by extension plant parts (leaf/stem/pistol/etc.) extract, isolate, various processed representations, commercial or medical consumable products.
  • the system is premised on single source of Scientific Sample’s during the genetic authentication process. Users may query Scientific Sample’s based on one or more representations, but these representations stem from a single genetic source.
  • Hybrids derived during the genetic verification process may contain more than one source of Scientific Sample’s, but genetic authentication, enzyme analysis, and receptor affinity, selectivity, and efficacy is derived from a single source of Scientific Sample’s. Verified products are labeled with a unique identifier, i.e.
  • dNFT dynamic non-fungible token using the ERC 1155 standard
  • Dynamic scoring and ranking create a live view of the market for consumers. A consumer seeking a strain of cannabis intending to stimulate analgesic receptors will use this system to find the highest-ranking strain. Furthermore, the system allows the consumer to determine the highest-ranking strain with multi-receptor activity, enabling a new level of qualitative and quantitative consumer analysis.
  • Dynamic scoring and ranking of a strains ability to stimulate particular receptors as well as for affinity, efficacy and selectivity at a particular receptor enables qualitative and quantitative valuation. When two or more strains are comparatively ranked by features, the consumer perceives benefit and makes rational selections. Perceived benefits also enable the ranking between strains and external products (i.e., Pharmaceuticals) with similar beneficial properties.
  • Dynamic scoring and ranking create a live view of the pricing for manufacturers. Dynamic scoring and ranking will drive consumer sentiment, when captured this activity will drive the decision making of manufactures; and selecting strains for products will be driven by consumer sentiment.
  • Ranking consists of the following critical elements. 1st, fit with receptor of interest hereunto known as receptor affinity.
  • Receptor affinity will be based off isolated compounds of interest associated with attributes or possible claims of value-add biologically active agent’s capability to bind to a particular receptor.
  • These receptors include but are not limited to central nervous system associated systems including cannabinoid and dopaminergic receptors as well as opioids ( Figure 11).
  • 2 nd activity at said receptor hereunto known as receptor efficacy.
  • Efficacy will be measured by determining ability of isolated compounds of interest associated with attributes or possible attributes of value-add biologically active agent’s capability to not only bind but also activate receptors of choice as measured by particular assays of choice. Full agonists, partial agonists, reverse agonists and antagonists will be determined.
  • [079] 3 rd expression efficiency of key enzymes responsible for production of isolated compounds of interest.
  • Compounds of interest such as, meroterpenoids from cannabis plants, are biosynthesized by complex chemical pathways dictated by particular enzymes that are themselves coded for by particular genes. The % expression of these genes determine the amount and efficiency of enzymes 88209.413709 produced isolated compounds of interest. This feature is captured within the ranking system as attributes to consistency of quantity with a particular compound.
  • selectivity of the receptors over other targets will also be incorporated in, determining an overall score of the compound in question according to the Scientific Sample scale. Selectivity will include the ability to bind to and stimulate a receptor at a higher ratio and percentage than others.
  • Scoring will entail weighted averages of receptor affinity, contrasted with efficacy or lack thereof at receptors, and factored against production of gene. Scoring will have the following equation: [081] Receptor Affinity (in where affinity ⁇ 100 nM will be scored on a sliding scale in where low numbers would result in higher “score.” An example would be ⁇ 1nM would correspond to a score of 10 while > 200 nM would score as a 1. [082] Receptor efficacy where efficacy will be measured with standard assays and scoring will be based on impact levels ranging from nM to pM with a weighted score given to more “potent” analogs.
  • Scoring will be on a highest score in which a 100 point scale in which 100 equals the highest levels of rank activity, selectivity efficacy and enzyme activity which directly translates into enzyme production. This score will then be given alongside the quality of a sample against biological target, such as pain/sleep/anxiety.
  • binding and efficacy concentration will be determined on a sliding scale based of nM concentrations such as follows ( Figure 12).
  • Ranking will be determined based off scores from assay results as well as perceived metric of pharmacological value based for WHO quality of life calculations and overall impact of QALYs also known as quality adjusted life year.
  • the Central Laboratory and Satellite Laboratories provide the intake for samples and ultimately document a subject’s genetic value, where value is established as a strain producing relevant biologically active components that can be attributed to claims of utility, purpose, and value. Furthermore, the Central Laboratory and Satellite Laboratories will establish a dynamic system to certify authenticity at various points throughout the supply chain, facilitate payment and purchase, and facilitate the scoring and dynamic ranking of genetic profiles, while the blockchain system serves as the bridge between both systems time-stamping a subject’s existence in a decentralized constellation of independent laboratories. [090] Clonership [091] The system employs the Clonership method to facilitate the application and restriction of naming configurations for genetic profiles.
  • the system enables genetic profile owners to register a brand, defined as a word, words, phrase, or design, or a combination that identifies a genetic profile, 88209.413709 distinguishing it from other genetic profiles. Once a genetic profile is registered within the system, and a brand assigned, genetic fidelity is defined by a 92% genetic match ⁇ 3% is required to use an assigned brand. Genetic profiles that fall outside of a 92% genetic match ⁇ 3% shall not use an assigned brand.
  • Clonership s blockchain-based time-stamping process, records data at the Central Laboratory or Satellite Laboratories, proving the sample’s existence and branding at a specific time and date, facilitating a first-to-file system for branding configurations, and establishing verification thresholds for comparative analysis and certification of its branding authenticity.
  • Figure 21 For example, Acapulco Gold is a well-known cannabis brand. The universe of products usurping the brand’s consumer recognition is broad, and its genetic footprint is vast. Acapulco gold products may share little genetic resemblance. Clonership identifies genetic parentage and creates a Novel range within the accepted confidence level. The time and date provide a first-to-file advantage within the system, documenting ownership, branding, and market relativity.
  • SNPs Single nucleotide polymorphisms
  • SNPs can occur all along the genetic sequence within organisms including plants. These SNPs may lend to unique characteristics within plants including cannabis. At this juncture, to the best of the inventors’ knowledge, SNPs are not being utilized to classify “parent” strains of cannabis nor are rapid sample preps facilitating the ability to test for SNPs amongst cannabis samples.
  • the present sample preparation in addition to lending itself for the extraction of compounds of interest is able to step further by also allowing the processing of genetic material to exploit and examine the actual SNPs that may be present resulting in differentiation of parent versus clone strains of cannabis plants.
  • bioinformatics will facilitate the analysis of quantification of differences between specific gene variations and will be facilitated by standardized statistical analysis where submitted parent/clone or hybrid materials will have measurements conducted from as submitted sample (DNA and/or otherwise) and using informatics approach, specific information will be captured. This stems from the ability to examine the individual alleles from genetics found in the 20 different chromosomes within the cannabis plant.
  • Hybrid strains will be clearly identified as such, as they will have similar yet distinct genes of interest and SNPs from parent material. This is in part due to the nature of hybrid strains having at least one other set of genetic origin material present within submitted samples. Comparative analysis via informatics to an existing database will demonstrate that hybrid strains will be no greater than a 95% match according to lower and upper threshold limits. Additionally, genes within hybrid strains themselves can be matched with good confidence to the original contributor strains when analytics falls between lower and upper thresholds. [098] Genomic measurement is facilitated by the sample preparations described herein. Upon sample preparation, various techniques to establish genetic origin can be utilized. These include the use of polymerase chain reaction to amplify genetic material and subsequent analysis of genetic material using the current state of technology and tools.
  • SNP genotyping and microarrays will be SNP genotyping and microarrays, along with standard Sanger style sequencing.
  • Other tools utilized to identify specific genes of interest will be fluorescent in situ hybridization, high throughout genotyping and comparative genomic hybridization to examine ploidy between samples submitted which will assist in the measurement of parent/clone and determination of such vs 88209.413709 hybrid strain samples.
  • Other genetic testing paradigms can be included and used as stand-alone or in combination to map out genetics of submitted sample materials for comparison. These assays are all amenable based on the rapid sample and preparation and processing described herein which differentiates from known standard protocol preparation, which typically require laboratory infrastructure to facilitate.
  • Enzymes of Interest Examination In addition to examination of cannabis alleles across the entire sequence of plants, the sample preparation will also facilitate specific examination of key genetic characteristics. In particular, enzymes themselves involved with meroterpenoid synthesis. Type III polyketide synthase (PKS), olivetolic acid cyclase (OCAC), THC-A synthase (THCA-syn) and CBD-A synthase (CBDA-syn) are the key enzymes involved in the production of the key intermediates as well as the meroterpenoids of interest within the cannabis plant.
  • PPS polyketide synthase
  • OCAC olivetolic acid cyclase
  • THCA-syn THC-A synthase
  • CBD-A synthase CBD-A synthase
  • THCA-syn polymorphism can lead to the production and variation of the amount of psychoactive materials produced in cannabis plants.
  • the method described herein facilitates testing for the present of the level of expression of particular enzymes as well as for any polymorphisms.
  • Polymorphisms in THCA- syn for example can heavily influence and dictate the amount of psychoactive components within a cannabis plant and identification of polymorphisms provide end users with an accurate approximation of how much several particular meroterpenoids per weight basis will be present within the plant.
  • polymorphisms within key enzymes such as THCA- syn can also be used as a “fingerprinting” technique to determine strain of various cannabis plants as well as origin, i.e. male/female/parent/clone. 88209.413709
  • THCA- syn a “fingerprinting” technique to determine strain of various cannabis plants as well as origin, i.e. male/female/parent/clone. 88209.413709
  • the present cassette device in addition to the sample preparation that follows, facilitates ease of sample process and testing for particular elements involving enzymes, stemming from the SNPs that dictate these.
  • SNPs single nucleotide polymorphisms
  • SNPs within the genetic sequence of enzymes provide more detailed identification of cannabis strains and associated enzymes that produce secondary metabolites of interest, such as the meroterpenoids.
  • the advantage lies in the fact that a SNP with the enzyme may alter the fidelity and function of key enzymes, however, the SNPs may also be silent in terms of activity but still differentiate strains, further helping to isolate patentable strains from the existing genetic diversity that exists within cannabis strains.
  • SNPs are not being utilized to defend patent position and the current methodology will facilitate differentiation of strains via presence of specific enzyme (aforementioned) expression as well as particular SNPs of interest within each of these enzymes, thus allowing a higher and more precise level of identification of unique strains and enzymatic features of interest for cannabis plants.
  • Identification of SNPs that code for the enzymes that in turn determine the level of meroterpenoids within a sample is advantageous as introduced a level of consistency that is currently not seen within cannabis production.
  • the ability to specifically know how much and which meroterpenoid will be present within a sample will, according to current knowledge, for the 1 st time, allow producers to definitely make claims specific to their strain of cannabis.
  • THCA-syn enzymes and associated polymorphisms of which 16 are of note, will be examined but not alone, examination via the sample preparation will allow for determination of CBDA-syn as well including potential polymorphisms identified as standard which in this case refer to high THC-A synthase expressing strains.
  • SNPs can occur within strains of cannabis alone, or numerous SNPs at key positions on the alleles can occur, each of which can be captured and identified to establish identity of strains. Again, the utilization of SNPs to establish identity of cannabis strain via the enzymes that produce secondary metabolites is not appreciated within the field and will be facilitated via the present embodiments of sample preparation and testing.
  • Non-fungibility is a basis for the embodiments described herein; records certifying genetic confirmation and supply chain validation as true and accurate. Recorded in blockchain, they are certified authentic, and cannot be copied, substituted, subdivided, or assigned to another genetic signature.
  • Blocks of data are controlled and confirmed by a decentralized ledger system managed by multiple public blockchain nodes and a network.
  • the system s public blockchain nodes operate at each satellite 88209.413709 laboratory and the Central Laboratory. All laboratories issue blocks of data representing digital assets identified by a smart contract on the blockchain.
  • dNFT Dynamic Non-Fungible Tokens
  • the Central Laboratory After establishing an account, the Central Laboratory issues a scientific sample cassette or cassettes to the sample owner. Initially, cassettes are identified by QR CODE. Associated metadata, at a minimum, should include unique IDs assigned to identify the account holder and the sample lot.
  • the cassette is sent to the account holder; once received, the sample is inserted into the cassette and sent to a satellite laboratory for general screening that may include: residual solvents, pesticides, potency, terpenes, heavy metals, mycotoxin, moisture, water activity, pathogenic microbiology, PAH, qPCR, and filth and foreign materials.
  • a satellite laboratory for general screening that may include: residual solvents, pesticides, potency, terpenes, heavy metals, mycotoxin, moisture, water activity, pathogenic microbiology, PAH, qPCR, and filth and foreign materials.
  • This Novel approach enables third-party genetic verification without broadcasting an entire database of genetic profiles and can be used to verify any volume of homogenous genetic material (Figure 8). If the sample is suspected to be a Novel genetic profile, the sample is sent to the Central Laboratory for genetic profile analysis. [0113] Once established in the Central Database, future samples will be identified by a Dynamic Non-fungible Token. The sample’s account holder may verify genetic material to an existing genetic profile at a satellite laboratory. The targeted genetic profile is contained within the sample’s unique identifier, a dNFT (dynamic non-fungible token using the ERC 1155 standard and containing a QR code).
  • dNFT dynamic non-fungible token using the ERC 1155 standard and containing a QR code
  • the QR code within the dNFT holds a maximum of 7089 numeric characters, 4296 alphanumeric characters, or 2953 alphanumeric characters with spaces and 88209.413709 punctuation is the physical limit of a QR code, as defined by ISO/IEC 23941:2022 standards. These characters are used to scientifically describe the genetic profile control material rather than requiring physical control material to test.
  • Figure 13 Genetic profile in this regard refers to enzymatic production and the presence of key compound-producing enzymes ( Figure 7). In particular, this is THC-A Synthase, the key enzyme, and reactor to produce base compounds found within the cannabis plant into THC/THC-related compounds.
  • Efficacy and receptor activation are critical to biological activity as activation of a receptor and subsequent signaling leads to the observable biological and pharmacological phenomenon observed. Efficacy as a differentiator will show which strains produce and have compounds that can be associated with an observed biological outcome. [0117] Another measurable attribute pertains to selectivity. Selectivity in this context refers to the isolated and extracted compounds from plant samples and how selective they are with respect to which receptors these compounds display affinity and/or efficacy to. Selectivity also differentiates samples by demonstrating that compounds produced by samples are more or less promiscuous in terms of pharmacological activity. This is key as selective compounds can differentiate and discern which samples trigger response biologically, translating to an attribute of the sample source material (Figure 15).
  • Each concept can be associated with multiple representations, including schematics of overlays from the genetic makeup of each plant strain sample as it relates to the physical-chemical products produced, including rations and how these may or may not stimulate 88209.413709 pharmacologically relevant receptors and the likelihood that this stimulation leads to statistically significant or documented clinically significant response.
  • the satellite laboratory verifies a sample matching within the accepted confidence level an existing genetic profile scientifically described within the dNFT, then the sample is confirmed certified within the blockchain system, and may be sold or contained in other products while baring the certified brand, and marketing its genetic features (Figure 23).
  • De novo, genetic profile analysis is completed at the Central Laboratory. Upon arrival, the sample’s identifying label is scanned.
  • the sample is then tested for genetic identification, as defined in the genetic identification section. If the sample is once again confirmed de novo, Clonership, receptor scoring & ranking, and enzyme detection may continue ( Figure 19). [0122] If the sample is de novo, then the sample account holder may brand the genetic profile, as described in the Clonership process. [0123] If the sample matches within the accepted confidence level an existing genetic profile contained within the Central Laboratory System, the sample owner may license the branding reserved within the Clonership process. The sample owner may not establish a new brand within the established confidence level for an existing genetic profile. [0124] If the sample does not match an existing genetic profile, the genetic profile is considered de novo, and the Clonership process, receptor scoring, and enzyme detection may occur. These data comprise the scientific sample’s genetic profile.
  • Data may be queried by one or more physical receptors or possibly by products ranked by receptor stimulation or receptor stimulation potency, including but not limited to affinity, selectivity, and efficacy at said pharmacological receptors; by geographic location, manufacturer, brand, or retail establishment. They also may be queried by specific item or lab result (Figure 15) with the location of strain associated back to genetic variability historically associated with indigenous plant samples of the region.
  • the system issues the parentage owner a unique identifier (i.e., Dynamic Non-fungible Token (dNFT) assigned to the genetic parentage. Consumers may use computer applications to scan this unique identifier and find on-chain and off- chain data attributed to the product ( Figure 23).
  • dNFT Dynamic Non-fungible Token
  • the cassette device provides the ability to process a sample rapidly for in vitro pharmacological testing of a unique suite of receptors that are considered to then link to show desired biological effects.
  • the cassette provides the milieu to conduct such testing at each level via its innovative design and sample preparation.
  • a self-contained sample capture and processing unit for the collection and transportation of genetic material comprising: a self-contained sample capture and processing unit that allows for the extraction and isolation of compounds of interest within cannabis plants used to establish genetic parentage, wherein a.
  • the method for capture and/or processing allows for ease of transport without the disruption of regulatory statues as non- regulated material from the cannabis plant is extracted (the stems); and, b.
  • a method of measuring, scoring or ranking receptor stimulation by cannabis or hemp strains by employing genetic diagnostic testing on a seed or a plant sample, wherein a.
  • a genetic diagnostic test resulting in the establishment of a genetic control with a test requiring a minimum of (30 samples), with results indicating a confidence level of ( ⁇ 95%) of the genome map and identification of genetic markers indicating stimulation of one or more physical receptors, as well as particular SNPs of interest for metabolizing enzymes germane to the production of compounds of interest; in which the scoring system works in sections of an algorithm, wherein the algorithm components comprise: selectivity of compounds produced and extracted from plant at biological receptors of interest.
  • Efficacy at biological receptors, Levels of affinity at biological receptors and qualitative production of enzymes responsible for the synthesis of compounds of interest in plant based off genetic identification wherein b. Precision diagnostic tests resulting in the scoring of the potency of the physical receptor stimulation at the cannabis or hemp seed or cultivation; and/or c. Genetic traceability, diagnostic test or tests to confirm the genetic identification throughout the supply chain post cultivation, 88209.413709 wherein confirming the genetic identity within extraction, processing, and/or manufacturing; d. Genetic parentage, uniquely identified by Dynamic Non-fungible Token (dNFT); and e. Laboratory results are time-stamped and secured by blockchain, and/or centrally archived.
  • dNFT Dynamic Non-fungible Token
  • a computer-implemented method for grouping genetic diagnostic results from one or more laboratory systems wherein satellite laboratory data is transferred and centrally processed and stored, wherein the transfer of the genetic diagnostic results is secured and time-stamped using blockchain, wherein a centralized data repository verifies a blockchain contract transactions, then translates, normalizes, scores, and/or ranks, genetic diagnostic results before storing the data in a centralized data repository, wherein the method includes a.
  • a genetic diagnostic test confirming the genetic match between (30 samples), with results indicating a confidence level of ( ⁇ 95%); and/or
  • Genetic diagnostic test resulting in the scoring of the potency of the physical receptor stimulation of the cannabis or hemp seed or cultivation.
  • Genetic diagnostic test resulting in the selectivity of physically stimulated receptors of the cannabis or hemp seed cultivation; and, d. Laboratory results are time-stamped and secured by blockchain, and/or centrally archived.
  • Laboratory results are time-stamped and secured by blockchain, and/or centrally archived.
  • One or more genetic diagnostic tests indicating a confidence level of ( ⁇ 95%) of the genome map and identification of genetic markers indicating stimulation of one or more physical receptors indicating Clonership; and/or b.
  • a self-contained sample capture and processing unit identified by a Dynamic Non fungible Token (dNFT) containing on-chain and off-chain reference information that are time-stamped, secured by blockchain, and centrally archived, and attached to a self-contained sample capture, processed cannabis or hemp, or commercial product.
  • dNFT Dynamic Non fungible Token
  • a. Contains on-chain data identifying genetic parentage name, time- stamp within the system, parentage ownership, reference numbers; and, b. Contains on-chain data identifying the genetic parentage profile, containing on-chain data that including Clonership identification via informatic approach of genetic materials; and, 88209.413709 c.
  • a system comprising satellite laboratories having directed genetic diagnostic results to a centralized data repository using a blockchain-based decentralized satellite system portal by executing blockchain contracts, genetic diagnostic results shall associate and be mapped to at least one receptor assay data set in the centralized data repository’s assay engine & resolver module, the centralized data repository having the genetic diagnostic results associated with at least one receptor or more data sets used to map the genetic diagnostic results, a method for managing at least one receptor assay in the centralized data repository, the method comprising: a. an act of receiving a genetic diagnostic results from the satellite laboratory workstation via the decentralized satellite system portal, wherein the result is associated with blockchain contract interface code provided by the centralized data repository; and/or, b.
  • a method for modifying the content of a centralized data repository by a decentralized satellite system comprising: a. A step for determining a current representation of current physical location of data stored in the centralized data repository; and/or, b. an act of altering the decentralized satellite system’s current data representation without altering the physical receptor data in the centralized data repository; and/or, 88209.413709 c. A step for receiving input from the decentralized satellite system that identifies a new representation for the current physical location data; and/or, d.
  • a method for accessing verified results of a centralized data repository by remote users comprising: a. A step for accessing a current representation of blockchain contracts stored in the centralized data repository indicating the current ranking of cannabis and or hemp strains by the receptors; and/or, b.
  • Representations are limited to one source of genetic diagnostic results; and, e. Genetic diagnostic results is limited to one genetic source.
  • 88209.413709 A method of using a centralized data repository to map genetic diagnostic results, in addition to other pertinent in vitro pharmacological results including but not limited to composition of matter and target of activity, i.e. physical receptor, received from a decentralized satellite system for storage in a centralized data repository, a method for mapping representations of the laboratory data genetic diagnostic results to the centralized data repository, the representations provided by the decentralized satellite system, the method comprising: a.
  • a step for receiving a current representation identified by the decentralized satellite system and/or, b. a step for searching the centralized data repository for the current representation; and, c. a step for searching the centralized data repository for the current ranking and scoring of genetic diagnostic results; and, d. a step for searching the centralized data repository receptors stimulation potency, including but not limited to affinity, selectivity and efficacy at tested receptors; and, e. a step for searching centralized data repository of enzymes and isoforms of enzymes of interest; and, f. a step for receiving instructions from decentralized satellite system; and, g. a step for managing the current representation in accordance with the receive; and, h. instructions such that the current representation is mapped to the centralized data repository.
  • a method of creating fractional dNFTs to track and manage more than one owner of a genetic profile a. A step for submitting parentage ownership proof; and, 88209.413709 b. A step for creating and deploying the smart contract; and, c. A step for assigning fractional ownership by shares; and, d. A step for entering the contract address; and, e. A step for entering the image; and, f. A step for entering metadata identifying genetic parentage name, time-stamp within the system, parentage fractional ownership, reference numbers; and, g. A step for entering metadata identifying genetic parentage name, time-stamp within the system, parentage ownership, ownership status, reference numbers; and, h.
  • a step for entering metadata referencing dynamic comparative data comprising other parentage profiles and genetic diagnostic results, their stimulation of various receptors, and a scoring of the potency of their effect on specific receptors, with a comparative ranking against one or more strains stimulating the same receptor; Contains off-chain data referencing dynamic comparative data comprising ratio of compounds presence compared to known 88209.413709 reference samples as well as selectivity of receptors stimulated; and, m.
  • a step for entering metadata referencing location restrictions; and, p. A step for entering metadata referencing various regulatory approvals and clinical data; and, q.
  • a method of creating dNFTs to track and manage one owner of a genetic profile a.
  • a step for deploying the smart contract; and b. A step for entering the contract address; and c.
  • a step for entering the image; and, d. A step for entering metadata identifying genetic parentage name, time-stamp within the system, divided parentage ownership, reference numbers; and, 88209.413709 e.
  • a step for entering metadata referencing dynamic comparative data comprising other parentage profiles and genetic diagnostic results, their stimulation of various receptors, and a scoring of the potency of their effect on specific receptors, with a comparative ranking against one or more strains stimulating the same receptor; Contains off-chain data referencing dynamic comparative data comprising ratio of compounds presence compared to known reference samples as well as selectivity of receptors stimulated; and, k.
  • a step for entering metadata referencing location restrictions; and, n. A step for entering metadata referencing various regulatory approvals and clinical data; and, o.
  • a system comprising a laboratory, central data repository, and dNFTs immutably linked to a specific genetic parentage to track and manage the verification, purchase, and payment for hemp and cannabis within a supply chain, as well as tracking payments to licensees to licensors, and payments to government authority.
  • a. A step for a laboratory accepting a shipment of cannabis or hemp into an inventory management system by scanning an attached dNFT; and, b.
  • a step for verifying a sample matches a requested genetic parentage within the dNFT; a, e.
  • the present invention provides 1.
  • An apparatus for the collection and transportation of genetic material comprising: a self-contained sample capture and processing unit for the extraction and isolation of compounds of interest within cannabis plants, wherein the self-contained sample capture apparatus provides for a.
  • a cannabis plant source from a cannabis source within the self-contained sample capture apparatus suitable for transportation of genetic material; b. qualification and quantification of chemical compounds of interest (meroterpenoids) identified from the cannabis plant source within the self-contained sample capture apparatus; c. a receptor screening assay is performed with clinical data read- outs from the cannabis plant source within the self-contained sample capture apparatus, wherein cannabis source is extracted to provide the cannabis plant source; and d. the extracted cannabis plant source is identified by QR Code, or Dynamic Non-fungible Token (dNFT) including selectivity, affinity and/or efficacy at receptors of interest.
  • dNFT Dynamic Non-fungible Token
  • a self-contained sample capture and processing unit that provides extraction and isolation of specific genetic testing for key genetic 88209.413709 markers within cannabis plant material including entire genome mapping, wherein the self-contained sample capture and processing unit provides: a. key enzymes of genetic sequences in the cannabis plants that produce chemical compounds of interest (meroterpenoids), including identification of isoforms of enzymes of interest; b. clonership identification via an informatic approach of genetic materials including the identification of parent, clone and/or hybrid strain of samples that are identified by QR Code, or Dynamic Non-fungible Token (dNFT); and c. archiving laboratory results that are time-stamped and secured by blockchain, and centrally archived, wherein the cannabis plant material is extracted within the self-contained sample capture unit.
  • key enzymes of genetic sequences in the cannabis plants that produce chemical compounds of interest (meroterpenoids), including identification of isoforms of enzymes of interest
  • b. clonership identification via an informatic approach of genetic materials including the identification of parent, clo
  • a method of measuring, scoring and/or ranking receptor stimulation by cannabis or hemp strains by employing genetic diagnostic testing on a seed or a plant sample provided by: a. a genetic diagnostic test resulting in the establishment of a genetic control with a test requiring a minimum of 30 samples, with results indicating a confidence level of ( ⁇ 95%) of the genome map and/or identification of genetic markers indicating stimulation of one or more physical receptors, as well as particular SNPs of interest for metabolizing enzymes in which the scoring system works in sections of an algorithm, wherein the algorithm components are: selectivity of compounds produced and extracted from a plant sample with biological receptors based on genetic identification; 88209.413709 b.
  • a computer-implemented method for grouping genetic diagnostic results from one or more laboratory systems wherein satellite laboratory data is transferred and centrally processed and stored, wherein the transfer of genetic diagnostic results is secured and time-stamped using blockchain technology, wherein a centralized data repository verifies blockchain contract transactions, then translates, normalizes, scores, and/or ranks, genetic diagnostic results before storing the data in a centralized data repository, wherein a. a genetic diagnostic test confirms the genetic match between 30 samples, with results indicating a confidence level of ( ⁇ 95%) and b. genetic diagnostic testing resulting in the scoring of the potency of the physical receptor stimulation of the cannabis or hemp seed or cultivation.
  • a genetic diagnostic test resulting in the measurement of the potency of the physical receptor including one or more of affinity, selectivity and/or efficacy at a particular receptor; and/or 88209.413709 c. a method of ranking of the potency of the physical receptor stimulation against one or more genetic strains stimulating the same receptor; and/or d. a method of ranking of the potency of the physical receptor stimulation against one or more genetic strains stimulating the same receptor in addition to a comparison of stimulation levels for each receptor.
  • Satellite Laboratories sending genetic diagnostic results to a centralized data repository using a blockchain-based decentralized satellite system portal, wherein executing blockchain contracts or genetic diagnostic results are mapped to at least one receptor assay data set in the centralized data repository’s assay engine and/or a resolver module, the centralized data repository having the genetic diagnostic results associated with at least one receptor or more data sets used to map the genetic diagnostic results, the method comprising: a. receiving a genetic diagnostic result from the satellite laboratory workstation via the decentralized satellite system portal, wherein the result is associated with a blockchain contract interface code provided by the centralized data repository; and/or b. searching blockchain contracts within the centralized data repository for the assay results, wherein the genetic diagnostic results are compared to one or more assay results associated with one or more physical receptors.
  • a method for modifying the content of a centralized data repository by a decentralized satellite system comprising: a. determining a current representation of current physical location data stored in the centralized data repository; 88209.413709 b. altering the decentralized satellite system’s current data representation without altering the physical receptor data in the centralized data repository; c. receiving input from the decentralized satellite system that identifies a new representation for the current physical location data; d. modifying the current representation to the new representation without affecting a receptor identifier associated with the current representation; and e. storing the new representation to the centralized data repository.
  • a method for accessing verified results of a centralized data repository by remote users comprising: a.
  • a current representation of blockchain contracts stored in the centralized data repository indicating the current ranking of cannabis and/or hemp strains by receptors accessing a current representation of blockchain contracts stored in the centralized data repository indicating the current ranking of cannabis and/or hemp strains by receptors; b. accessing the current representation of blockchain contracts stored in the centralized data repository indicating the current ranking of cannabis and/or hemp strains by the receptors stimulation potency, including but not limited to affinity, selectivity and/or efficacy at tested receptors; and c. accessing the current representation of blockchain contracts stored in the centralized data repository indicating the current ranking of cannabis and/or hemp strains by the receptors stimulation potency ranking, wherein representations are limited to one source of genetic diagnostic results; and/or genetic diagnostic results are limited to one genetic source.
  • a system including a centralized data repository for mapping genetic diagnostic results in addition to in vitro pharmacological results including composition of matter and target of activity, received from a decentralized satellite system for storage in a centralized data repository, resulting in a method for mapping representations of laboratory data genetic diagnostic results to the centralized data repository, wherein the method comprises: a. receiving a current representation identified by the decentralized satellite system; b. searching the centralized data repository for the current representation; c. searching the centralized data repository for the current ranking and scoring of genetic diagnostic results; d. searching the centralized data repository receptors stimulation potency, including but not limited to affinity, selectivity and efficacy at tested receptors ; e.
  • a method of creating fractional dNFTs dynamic Non-Fungible Token) to track and manage more than one owner of a genetic profile comprising a. submitting parentage ownership proof; b. creating and deploying a smart contract; c. assigning fractional ownership by shares; d. entering the smart contract address; 88209.413709 e. entering an image of a QR code of a dNFT; f.
  • a method of creating Dynamic Non-Fungible Tokens (dNFTs) to track and manage one owner of a genetic profile comprising a.
  • deploying a smart contract b. entering the smart contract address; c. entering an image of a QR code of a dNFT; d. entering metadata identifying genetic parentage name, time-stamp within the system, divided parentage ownership, and/or reference numbers; e. entering metadata identifying genetic parentage name, time-stamp within the system, parentage ownership, ownership status, and/or reference numbers; 88209.413709 f. entering metadata identifying the genetic parentage profile, containing on-chain data that includes Clonership identification via an informatic approach of genetic materials; g. entering metadata identifying key enzymes and genetic sequences in the cannabis plants that produce chemical compounds of interest (meroterpenoids), including that of any and all isoforms of enzymes of interest; h.
  • a system comprising a laboratory, central data repository, and Dynamic Non-Fungible Tokens (dNFTs) linked to a specific genetic parentage to track and manage verification, purchase, and/or payment for hemp and/or cannabis within a supply chain, as well as tracking payments from licensees to licensors, and/or payments to a government authority, the system including a. accepting a shipment of cannabis or hemp into an inventory management system by scanning an attached dNFT; b. testing a sample of the shipment to verify it matches the purported parentage within the dNFT; c. accepting payment for a shipment; d. verifying a sample matches a requested genetic parentage within the dNFT; e.
  • dNFTs Dynamic Non-Fungible Tokens

Landscapes

  • Engineering & Computer Science (AREA)
  • Computer Security & Cryptography (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de création et de traitement d'échantillons de produits végétaux et de matériaux sources de cannabis en vue d'une analyse en profondeur. Le procédé facilite l'isolement et l'extraction fermée de composés chimiques d'intérêt à partir de la plante à la fois à des fins de qualification et de quantification. En outre, le procédé décrit ici, en raison de sa capacité à libérer du matériel génétique, permet l'examen et l'analyse de gènes clés spécifiques pour des enzymes impliquées dans la production de composés chimiques d'intérêt à l'intérieur de la plante. Enfin, le procédé décrit ici permet une analyse complète de génomes végétaux en raison du traitement de la plante qui va libérer du matériel génétique à des fins d'analyse. Le procédé de mise en œuvre de l'analyse permet un test grâce à la libération préparatoire par un échantillon spécifique de matériaux d'intérêt, tandis que le processus permet de contourner les restrictions concernant les produits réglementés car il se déroule à l'intérieur d'une unité autonome qui prépare les échantillons en vue d'une analyse approfondie.
PCT/US2024/044062 2023-08-29 2024-08-27 Nouvel échantillonnage et comparaison génétique et analyse de composants du cannabis pour une différenciation commerciale Pending WO2025049491A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363579334P 2023-08-29 2023-08-29
US63/579,334 2023-08-29

Publications (1)

Publication Number Publication Date
WO2025049491A1 true WO2025049491A1 (fr) 2025-03-06

Family

ID=94820243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/044062 Pending WO2025049491A1 (fr) 2023-08-29 2024-08-27 Nouvel échantillonnage et comparaison génétique et analyse de composants du cannabis pour une différenciation commerciale

Country Status (1)

Country Link
WO (1) WO2025049491A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227370A1 (en) * 2004-03-08 2005-10-13 Ramel Urs A Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays
US20170059536A1 (en) * 2015-09-01 2017-03-02 Orange Photonics, Inc. Cannabinoid concentration analyzer and method
US20190256888A1 (en) * 2013-06-12 2019-08-22 The General Hospital Corporation Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
WO2022101398A1 (fr) * 2020-11-13 2022-05-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. Ensemble de collecte d'échantillons authentifiable destiné à la collecte d'échantillons de végétaux et son utilisation
US20230037728A1 (en) * 2021-08-09 2023-02-09 Allele Group LLC Software, methods, and systems for blockchain-recorded transactions of real-world assets

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227370A1 (en) * 2004-03-08 2005-10-13 Ramel Urs A Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays
US20190256888A1 (en) * 2013-06-12 2019-08-22 The General Hospital Corporation Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
US20170059536A1 (en) * 2015-09-01 2017-03-02 Orange Photonics, Inc. Cannabinoid concentration analyzer and method
WO2022101398A1 (fr) * 2020-11-13 2022-05-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. Ensemble de collecte d'échantillons authentifiable destiné à la collecte d'échantillons de végétaux et son utilisation
US20230037728A1 (en) * 2021-08-09 2023-02-09 Allele Group LLC Software, methods, and systems for blockchain-recorded transactions of real-world assets

Similar Documents

Publication Publication Date Title
Lobo et al. Identification and validation model for informative liquid biopsy-based microRNA biomarkers: insights from germ cell tumor in vitro, in vivo and patient-derived data
Zhou et al. Authenticity and geographic origin of global honeys determined using carbon isotope ratios and trace elements
Hocquette Where are we in genomics?
Maliepaard et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective
Girelli et al. Traceability of “Tuscan PGI” extra virgin olive oils by 1H NMR metabolic profiles collection and analysis
Pereira et al. From the field to the bottle—an integrated strategy for wine authenticity
Tafesse et al. Genome-wide association mapping for heat and drought adaptive traits in pea
CN109872792A (zh) 一种用于指导精准用药的基因检测智能报告系统
Raja Sundari Balachandran et al. DNA barcoding: a genomic-based tool for authentication of phytomedicinals and its products
Tsimidou et al. Strategic priorities of the scientific plan of the European Research Infrastructure METROFOOD-RI for promoting metrology in food and nutrition
CN110033842A (zh) 一种含数据字典信息管理模块的精准用药智能报告系统
Savoi et al. Grapevine and wine metabolomics-based guidelines for FAIR data and metadata management
Raclariu-Manolică et al. DNA barcoding and metabarcoding for quality control of botanicals and derived herbal products
Lawrie et al. Agrigenomic diversity unleashed: current single nucleotide polymorphism genotyping methods for the agricultural sciences
Tomkowiak et al. Selection of parental material to maximize heterosis using SNP and SilicoDarT markers in maize
Burnett et al. A new approach method for characterizing inter-species toxicodynamic variability
CN110010222A (zh) 一种基于精准用药知识库的基因身份识别系统
Zhou et al. Genome Wide Association Study Identifies Candidate Genes Related to the Earlywood Tracheid Properties in Picea crassifolia Kom.
Ma et al. Advancing Stable Isotope Analysis for Alcoholic Beverages’ Authenticity: Novel Approaches in Fraud Detection and Traceability
Rus et al. Dried blood spot (DBS) methodology study for biomarker discovery in lysosomal storage disease (LSD)
WO2025049491A1 (fr) Nouvel échantillonnage et comparaison génétique et analyse de composants du cannabis pour une différenciation commerciale
CN110021442A (zh) 一种含用药知识库信息管理模块的精准用药智能报告系统
Carrara et al. A molecular toolbox to identify and quantify grape varieties: on the trace of “Glera”
Guerra et al. Genome-wide association of stem carbohydrate accumulation and remobilization during grain growth in bread wheat (Triticum aestivum l.) in mediterranean environments
CN110010200A (zh) 一种基因身份识别系统

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24860888

Country of ref document: EP

Kind code of ref document: A1